Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)

• Coronary CT scan with CAC score measurement (Other): Coronary CT scan with CAC score measurement (on the same day or within 6 months after the inclusion visit).

Primary outcomes

• Presence of subclinical coronary atherosclerosis [At the time of performing the coronary CT scan]: The criterion defining the presence of subclinical coronary atherosclerosis is the presence of at least one coronary stenosis greater than 50% in a main artery on coronary CT angiography

Secondary outcomes

• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: The anthropometric data collected as part of the current study will be comparable to the data collected as part of the SAFIR study
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: The clinic data collected as part of the current study will be comparable to the data collected as part of the SAFIR study
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: The drug treatments collected as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: The genetic data collected as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: The biological data collected as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: Arterial Doppler ultrasound of the carotid arteries and lower limbs as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: Pulse wave velocity measured by the pOpmeter as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: Hepatic steatosis as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: Hepatic fibrosis as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: Nutritional data as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: Physical activity as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with the presence or absence of subclinical coronary atherosclerosis (coronary stenosis > 50% on coronary CT scan). [30 months]: Quality of life as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: The anthropometric data collected as part of the current study will be comparable to the data collected as part of the SAFIR study
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: The clinic data collected as part of the current study will be comparable to the data collected as part of the SAFIR study
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: The drug treatments collected as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: The genetic data collected as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: The biological data collected as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: Arterial Doppler ultrasound of the carotid arteries and lower limbs as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: Pulse wave velocity measured by the pOpmeter as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: Hepatic steatosis as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: Hepatic fibrosis as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: Nutritional data as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: Physical activity as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Identification of factors associated with a coronary calcium score less than or equal to the 25th percentile [30 months]: Quality of life as part of the current study will be comparable to the data collected as part of the SAFIR study.
• Study of the association between the characteristics of coronary atheroma plaque on coronary CT and major cardiovascular events at 30 months. [30 months]: Semi-quantitative visual quantification of coronary stenoses on CT coronary angiography according to the CAD-RADS v2.0 classification and visual characterization of high-risk plaque features (vulnerability).
• Study of the association between the characteristics of coronary atheroma plaque on coronary CT and major cardiovascular events at 30 months. [30 months]: Quantification of total coronary atherosclerotic plaque, calcified and non-calcified, and by artery
• Study of the association between the presence of subclinical atherosclerosis (coronary stenosis > 50% on CT coronary angiography) and major cardiovascular events at 30 months [30 months]: Assess the association between the presence of significant coronary stenosis (>50% on a major artery) on coronary CT and the following major cardiovascular events: * Acute coronary syndrome or myocardial infarction * Coronary revascularization: angioplasty or bypass * Ischemic stroke * Carotid endarterectomy * Revascularization of a lower limb artery: angioplasty or bypass * Amputation related to PAD * Cardiovascular death
• Study of the association between the percentile of the coronary calcium score and major cardiovascular events and overall mortality at 30 months [30 months]: Assess the occurrence of major cardiovascular events and mortality according to the percentile of the coronary calcium score.
• Study of the association between arterial stiffness and major cardiovascular events and overall mortality at 30 months. [30 months]: Assess the occurrence of major cardiovascular events and mortality according to the measurement of arterial stiffness evaluated by pulse wave velocity measured with the pOpmeter
• Study of the association between the presence of hepatic steatosis and major cardiovascular events and overall mortality at 30 months [30 months]: Evaluer la survenue des événements cardiovasculaires majeurs et la mortalité en fonction de la stéatose hépatique
• Study of the association between the presence of liver fibrosis and major cardiovascular events and all-cause mortality at 30 months [30 months]: Assess the occurrence of major cardiovascular events and mortality according to the presence of liver fibrosis

Sex: All, ages: 40 Years to any

Inclusion Criteria:

* Person willing to sign the study consent form
* Person affiliated with a current social security scheme
* Person with a definite diagnosis of Familial Hypercholesterolemia, defined by a Dutch Lipid Clinic Network (DLCN) clinical-biological score > 8 and/or an identified causal mutation in the LDL receptor (LDLR) gene, apolipoprotein B100 gene, PCSK9 gene, or apolipoprotein E gene
* Male aged 40 years or older, or female aged 50 years or older
* Ability to understand French for questionnaire completion
* Person not taking any lipid-lowering medication or on a stable dose of lipid-lowering therapy for at least one month prior to inclusion (three months for PCSK9 inhibitors) at Visit 1
* Person not taking any antihypertensive medication or on a stable dose of antihypertensive therapy for at least one month at Visit 1
* Person not taking any antidiabetic medication or on a stable dose of antidiabetic therapy for at least 3 months at Visit 1

Exclusion Criteria:

* Subject with a technical contraindication for coronary CT scan: patient diameter > 70 cm and/or weight > 250 kg
* Patient with a history of atherosclerotic cardiovascular event (myocardial infarction, ischemic heart disease, coronary revascularization, ischemic stroke, carotid endarterectomy, lower limb arterial revascularization)
* Patient allergic to iodinated contrast agents
* Severe renal insufficiency: estimated glomerular filtration rate (eGFR) according to the CKD-EPI formula ≤ 30 ml/min
* Subject with active cancer or in remission for less than 3 years
* Subject who has received oral or intravenous corticosteroid therapy within the last 6 months
* Subject with untreated or poorly controlled hypothyroidism
* Subject receiving immunosuppressive or anticancer therapy
* Subject refusing to participate
* Subject under guardianship, curatorship, or judicial protection, or without social insurance coverage
* Pregnant woman